Quick Answer
Cytosorbents Corp reported R&D Expense of $15.73 million for fiscal year 2023.
Cytosorbents Corp R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2023 | $15.73M | +4.0% |
| 2022 | $15.12M | -7.7% |
| 2021 | $16.38M | +85.9% |
| 2020 | $8.81M | -27.1% |
| 2019 | $12.09M | +56.6% |
| 2018 | $7.72M | +139.8% |
| 2017 | $3.22M | -20.9% |
| 2016 | $4.07M | +5.2% |
| 2015 | $3.87M | +59.2% |
| 2014 | $2.43M | +39.8% |
| 2013 | $1.74M | -31.3% |
| 2012 | $2.53M | -12.3% |
| 2011 | $2.89M | +64.4% |
| 2010 | $1.76M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $1.85M | -50.6% | +21.8% |
| June 30, 2024 | $1.52M | -58.6% | -32.4% |
| March 31, 2024 | $2.25M | -46.7% | -40.0% |
| September 30, 2023 | $3.75M | +14.0% | +2.2% |
| June 30, 2023 | $3.67M | -12.3% | -12.9% |
| March 31, 2023 | $4.21M | -0.7% | +28.1% |
| September 30, 2022 | $3.29M | -22.8% | -21.4% |
| June 30, 2022 | $4.18M | +13.1% | -1.4% |
- Cytosorbents Corp showed an increase of +4.0% in R&D Expense compared to the prior fiscal year.
- Over the 2010–2023 period, Cytosorbents Corp’s r&d expense has grown by 795.0% (from $1.76 million to $15.73 million).
- The most recent figure is from Cytosorbents Corp’s fiscal year 2023 report (Form 10-K), filed with the SEC on March 15, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: